Results 11 to 20 of about 31,932 (244)

Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast [PDF]

Cancer Medicine, 2019
Purpose: Carcinosarcoma of the breast is a rare yet highly aggressive tumor accounting for \u3c1% of all breast cancers, for which guidance on optimal management and prognosis are sparse.
Acharya, Sahaja, Gabani, Prashant, Kennedy, William R, Thomas, Maria A, Zoberi, Imran   +4 more
core   +3 more sources

Clinicopathologic characteristics of mixed epithelial/mesenchymal metaplastic breast carcinoma (carcinosarcoma): a meta-analysis of Chinese patients

Polish Journal of Pathology, 2019
Breast carcinosarcoma is a rare and aggressive subtype of metaplastic breast cancer. Data focusing on breast carcinosarcoma is limited. The purposes of this study are to describe the clinicopathological features of breast carcinosarcoma and to evaluate ...
Dequan Xu, Limin Hou
doaj   +2 more sources

Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study

BMC Cancer, 2019
Background The clinical impact of adjuvant radiotherapy on uterine sarcoma is unclear, and may depend on the histological type. Hence, the aim of this study was to evaluate clinical outcomes of adjuvant radiotherapy after total hysterectomy in patients ...
Yuan Li, Haitao Ren, Junmei Wang
doaj   +2 more sources

A rare malignant thyroid carcinosarcoma with aggressive behavior and DICER1 gene mutation: a case report with literature review

Thyroid Research, 2018
Background Malignant biphasic tumor also known as carcinosarcoma is an uncommon neoplasm that is composed of both malignant epithelial and mesenchymal components. Most reported cases of carcinosarcoma affect the female genital tract; however, other sites
Jing Yang, Carmen Sarita-Reyes, David Kindelberger, Qing Zhao   +3 more
doaj   +2 more sources

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

Journal of Clinical Oncology, 2023
PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS ...
T. Nishikawa, K. Hasegawa, Koji Matsumoto, M. Mori, Y. Hirashima, K. Takehara, K. Ariyoshi, Tomoyasu Kato, S. Yagishita, A. Hamada, M. Kawasaki, S. Kawashima, Sawako Tomatsuri, Y. Nagasaka, H. Yoshida, R. Machida, A. Hirakawa, Kenichi Nakamura, K. Yonemori   +18 more
semanticscholar   +1 more source

Frontiers of Ovarian Carcinosarcoma

Current Treatment Options in Oncology, 2023
Ovarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less than 5% of ovarian cancers.
Ayden Ismail, Sunyoung Choi, S. Boussios
semanticscholar   +1 more source

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

Gynecologic Oncology, 2023
OBJECTIVES Carcinosarcomas are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements with heterogeneous HER2/neu expression and limited therapeutic options.
D. Mauricio, S. Bellone, L. Mutlu, B. McNamara, Diego D Manavella, Cem Demirkiran, M. S. Verzosa, N. Buza, P. Hui, Tobias M. Hartwich, J. Harold, Yang Yang-Hartwich, Margherita Zipponi, G. Altwerger, E. Ratner, Gloria S. Huang, M. Clark, V. Andikyan, M. Azodi, P. Schwartz, A. Santin   +20 more
semanticscholar   +1 more source

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Journal of Clinical Oncology, 2022
PURPOSE This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS).
M. Powell, V. Filiaci, M. Hensley, Helen Q. Huang, K. Moore, K. Tewari, L. Copeland, A. Secord, D. Mutch, A. Santin, D. Warshal, N. Spirtos, P. DiSilvestro, O. Ioffe, D. Miller   +14 more
semanticscholar   +1 more source

Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database

Journal of Clinical Medicine, 2023
Carcinosarcomas (malignant mixed Mullerian tumors) of a female genital organ are rare tumors associated with a poor survival. The purpose of this study was to identify site-specific differences in the incidence and prognosis in carcinosarcomas ...
Joo Won Lee, Y. Ouh, H. Chang, K. Min, Sanghoon Lee, J. Hong, J. Song, Jae-Kwan Lee, N. Lee   +8 more
semanticscholar   +1 more source

Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Cancer Research, 2022
Genomic analyses and preclinical models of ovarian carcinosarcoma support the conversion theory for disease development and indicate that microtubule inhibitors could be used to suppress EMT and stimulate antitumor immunity.
G. Ho, E. Kyran, J. Bedő, Matthew J. Wake fi eld, D. Ennis, H. Mirza, C. Vandenberg, Elizabeth Lieschke, Andrew Farrell, Anthony Hadla, R. Lim, G. Dall, J. Vince, Ngee Kiat Chua, O. Kondrashova, R. Upstill-Goddard, Ulla-Maja Bailey, Suzanne Dowson, P. Roxburgh, R. Glasspool, G. Bryson, A. Biankin, S. Cooke, Gayanie Ratnayake, O. Mcnally, Nadia Tra fi cante, Cancer Study, A. Defazio, S. Weroha, D. Bowtell, I. McNeish, A. Papenfuss, C. Scott, H. Barker, Eliza Hall   +34 more
semanticscholar   +1 more source